CM
DYN icon

Caption Management’s Dyne Therapeutics DYN Stock Holding History

Caption Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$1.26M – 1696
2025
Q3 		$1.26M Buy
+100,000
New +$1.14M 0.01% 1028
2024
Q1 		– Sell
-400,200
Closed -$5.32M – 1325
2023
Q4 		$5.32M Buy
+400,200
New +$3.91M 0.07% 309

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Caption Management's DYN Position: Q1 2026 in Review

Caption Management increased its Dyne Therapeutics (DYN) stake by 216% in Q1 2026, buying an estimated $93K and bringing the position to 7,894 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #1371.

Caption Management first reported a position in DYN in Q4 2023 and has held it in 3 quarters since. The position peaked at $2.49M in Q4 2023. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Caption Management held 7,894 shares of Dyne Therapeutics worth $143K as of Q1 2026.
  • Caption Management bought 5,394 Dyne Therapeutics shares in Q1 2026, an estimated $93K.
  • Dyne Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1371 holding.
  • Caption Management first reported a position in Dyne Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • Caption Management's Dyne Therapeutics position peaked at $2.49M in Q4 2023.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.